# US 8,785,446 B2 · Treating post-seizure patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,446 B2
- Document ID: US8785446B2
- Status: Granted
- Kind: B2
- Application number: 12/688,892
- Filed: 2010-01-17
- Published: 2010-07-22
- Granted: 2014-07-22
- Earliest claimed: 2009-01-17
- Assignees: Children's Medical Center Corporation
- Applicants: Frances E. Jensen; Sanjay N. Rakhade
- Inventors: Frances E. Jensen; Sanjay N. Rakhade
- Web page: https://patentgrep.com/patent/US8785446B2

## CPC

- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 38/13: Cyclosporins
- A61K 38/45: Transferases (2)
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Patients are subject to a post-seizure treatment regime to separately inhibitor consecutive targets of an epileptogenic cascade comprising neurotransmitter receptor signaling, kinase/phosphatase activity, protein translation, and apoptosis or inflammation.

## Claims

### Claim 1

A therapeutic method for treating a patient post-seizure comprising administering to the patient NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione), KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine), and rapamycin.

### Claim 2 (depends on 1)

The method of claim 1, further comprising administering to the patient epithalon, a corticosteroid, or a non-steroidal anti-inflammatory drug (NSAID).

### Claim 3 (depends on 2)

The method of claim 2, wherein NBQX, KN-62, rapamycin, and the corticosteroid or NSAID are administered sequentially,
wherein NBQX is administered first, within 24 hours post-seizure, the KN-62 is administered second, within 48 hours post-seizure, rapamycin is administered third, within 96 hours post-seizure, and the corticosteroid or NSAID is administered fourth, within 96 hours post-seizure.

### Claim 4 (depends on 1)

The method of claim 1, wherein NBQX, KN-62, and rapamycin are administered sequentially, wherein NBQX is administered first, within 24 hours post-seizure, KN-62 is administered second, within 48 hours post-seizure, and rapamycin is administered third, within 96 hours post-seizure.